Alpha Cognition Inc (ACOG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alpha Cognition Inc (ACOG) has a cash flow conversion efficiency ratio of -0.158x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.35 Million) by net assets ($33.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Alpha Cognition Inc market cap and net worth for the company's overall valuation and market capitalisation.
Alpha Cognition Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Alpha Cognition Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alpha Cognition Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alpha Cognition Inc ranked by their cash flow conversion efficiency. Explore ACOG cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Dividend Growth Split Corp Class A
TO:GDV
|
0.008x |
|
DR.Wu Skincare Co Ltd
TWO:6523
|
0.022x |
|
KB Star REIT Co. Ltd.
KO:432320
|
0.005x |
|
Bharat Wire Ropes Limited
NSE:BHARATWIRE
|
0.069x |
|
Eagle Cold Storage Enterprise Co Ltd
TWO:8905
|
0.038x |
|
Energy World Corporation Ltd
AU:EWC
|
-0.017x |
|
Ryder Capital Ltd
AU:RYD
|
-0.005x |
|
DongWon Development Co.Ltd
KQ:013120
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Alpha Cognition Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Alpha Cognition Inc from 2020 to 2024. View ACOG stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $41.46 Million | $-7.76 Million | -0.187x | -110.10% |
| 2023-12-31 | $-4.71 Million | $-8.73 Million | 1.852x | -73.54% |
| 2022-12-31 | $-1.32 Million | $-9.24 Million | 7.000x | +739.82% |
| 2021-12-31 | $9.03 Million | $-9.88 Million | -1.094x | +99.68% |
| 2020-12-31 | $16.01K | $-5.44 Million | -339.684x | -- |
About Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatm… Read more